Antisense Therapeutics to Present at Rodman & Renshaw Annual Global Investment Conference

| Source: Antisense Antisense

MELBOURNE, AUSTRALIA--(Marketwire - September 7, 2010) - Antisense Therapeutics Ltd. (ASX: ANP) today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 13, 2010 at 4:30pm Eastern time.

Mark Diamond, Antisense Therapeutics' Chief Executive Officer, will give the presentation which will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.antisense.com.au. A replay of the presentation will be archived for 90 days after the conference, at the same location. For more information about the Rodman & Renshaw Annual Global Investment Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

The conference will include a series of one-on-one meetings with institutional investors. Investors interested in scheduling a meeting with Mark Diamond, CEO of Antisense, can facilitate a request by contacting the Company at leslie.wolf-creutzfeldt@grayling.com or alternatively contact their Rodman & Renshaw representative directly.

Mr. Diamond will also attend the BioPharm America 2010 Conference in Boston between September 15th and 17th, and is available for meetings with investors in Boston during this time.

The Company recently announced significant progress on a number of licensing opportunities with respect to its product development pipeline which includes ATL1101 for Prostate Cancer, ATL1102 for Multiple Sclerosis and ATL1103 for Growth and Sight Disorders. Antisense has exclusive, worldwide rights for all applications of these 2nd generation antisense compounds which have been derived via the company's technology collaboration with Isis Pharmaceuticals (NASDAQ: ISIS).

About the Company

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of MRI lesions in patients with multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering the clinical stage of development as a potential treatment for growth and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for prostate cancer.

Website: www.antisense.com.au

Contact Information:

Contact Information

US Investors:
Investor Relations
Grayling
Ms. Leslie Wolf-Creutzfeldt
Phone: +1-646-284-9472
Email: leslie.wolf-creutzfeldt@grayling.com